Results for “continuous glucose monitor”

Diabetes Type 1

** Type 1 diabetes mellitus (T1D) is an autoimmune disorder in which the immune system destroys pancreatic β‑cells, leading to absolute insulin deficiency and chronic hyperglycaemia. **CONTENT:** ## Overview Type 1 diabetes (T1D) is a chronic, immune‑mediated disease that eliminates the pancreas’s ability to produce insulin, the hormone essential for moving glucose from the bloodstream into cells for energy. Without insulin, glucose accumulates in the blood, producing the classic triad of **polyuria** (frequent urination), **polydipsia** (excessive thirst), and **polyphagia** (increased hunger). Weight loss, blurry vision, fatigue, and delayed wound healing often accompany these primary signs. The onset is usually rapid; most individuals notice symptoms within weeks to a few months, prompting urgent medical evaluation. Management hinges on lifelong insulin replacement, delivered by injections or insulin pumps, combined with regular blood‑glucose monitoring, carbohydrate counting, and lifestyle adjustments. Advances such as continuous glucose monitors (CGMs) and hybrid closed‑loop systems have dramatically improved glycaemic control and quality of life. Nevertheless, T1D remains a lifelong condition that requires coordinated care from endocrinologists, diabetes educators, dietitians, and mental‑health professionals. **If you experience any of the hallmark symptoms, seek medical attention promptly**, as early diagnosis and treatment reduce the risk of acute complications like diabetic ketoacidosis (DKA). ## History/Background The first clinical description of “juvenile diabetes” dates to the 19th century, when physicians noted a distinct form of diabetes affecting children and adolescents. In 1921, Frederick Banting and Charles Best discovered insulin, transforming a fatal disease into a manageable condition. However, the autoimmune nature of T1D was not recognized until the mid‑20th century, when researchers observed autoantibodies targeting pancreatic islet cells. The 1970s brought the first assays for islet‑cell antibodies, confirming an immune‑driven process. In 1985, the World Health Organization formally distinguished **type 1** from **type 2** diabetes based on etiology and age of onset. Since then, genetic studies have identified HLA‑DR and HLA‑DQ loci as major susceptibility genes, and environmental triggers such as viral infections are under active investigation. ## Key Information - **Pathophysiology:** Auto‑reactive T‑cells infiltrate pancreatic islets, destroying >80 % of β‑cells before clinical symptoms appear. The loss of insulin leads to unchecked hepatic glucose production and peripheral insulin resistance. - **Epidemiology:** Approximately 5–10 % of all diabetes cases are type 1, affecting roughly 1.25 million people in the United States and 140 million worldwide. Incidence peaks between ages 4–7 and 10–14, but adult‑onset T1D is increasingly recognized. - **Diagnosis:** Criteria include fasting plasma glucose ≥126 mg/dL, 2‑hour oral glucose tolerance test ≥200 mg/dL, or HbA1c ≥6.5 % in the presence of autoantibodies (GAD65, IA‑2, ZnT8). - **Treatment:** Intensive insulin therapy aims for a target HbA1c <7 % (individualized). Options include rapid‑acting, long‑acting, and premixed insulin formulations, delivered via pens, syringes, or pumps. CGMs provide real‑time glucose data, enabling dose adjustments and reducing hypoglycaemia. - **Complications:** Chronic hyperglycaemia damages microvascular (retinopathy, nephropathy, neuropathy) and macrovascular (cardiovascular disease) systems. Acute emergencies include DKA, characterized by metabolic acidosis, ketonemia, and dehydration. - **Research Frontiers:** Immunotherapy (e.g., anti‑CD3 antibodies), β‑cell regeneration, and encapsulated islet transplantation aim to halt or reverse the autoimmune attack. Gene‑editing technologies such as CRISPR are being explored for durable cures. ## Significance Type 1 diabetes is a paradigm of autoimmune disease, illustrating how targeted immune dysregulation can devastate a single organ system. Its management has driven innovations in medical technology—most notably insulin analogues, pump therapy, and CGM devices—that have spilled over into broader diabetes care and chronic disease monitoring. Economically, T1D imposes substantial costs on health systems due to lifelong medication, monitoring supplies, and treatment of complications. Psychosocially, the disease shapes the daily lives of patients and families, influencing education, employment, and mental health. Understanding T1D also informs research into other autoimmune conditions, offering insights into tolerance, antigen presentation, and therapeutic modulation of the immune response. **Professional care reminder:** Anyone suspecting T1D should obtain urgent medical evaluation. Early insulin therapy prevents DKA, preserves residual β‑cell function, and improves long‑term outcomes. Regular follow‑up with a multidisciplinary diabetes team is essential for optimal disease control. **INFOBOX:** - Name: Type 1 Diabetes Mellitus - Type: Autoimmune endocrine disorder - Date: First described clinically in the 19th century; insulin discovered 1921; autoimmune mechanism clarified 1970s‑1980s - Location: Worldwide (global prevalence) - Known For: Absolute insulin deficiency caused by immune‑mediated β‑cell destruction **TAGS:** type 1 diabetes, autoimmune disease, insulin therapy, diabetic ketoacidosis, continuous glucose monitor, pancreatic β‑cells, endocrinology, chronic disease management